Discovery of 2-Phenylquinolines with Broad-Spectrum Anti- coronavirus Activity

A selection of compounds from a proprietary library, based on chemical diversity and various biological activities, was evaluated as potential inhibitors of the Severe phenotypic-based screening assay. A compound based on a 2phenylquinoline scaffold emerged as the most promising hit, with EC50 and CC50 values of 6 and 18 mu M, respectively. The subsequent selection of additional analogues, along with the synthesis of ad hoc derivatives, led to compounds that maintained low mu M activity as inhibitors of SARS-CoV-2 replication and lacked cytotoxicity at 100 mu M. In addition, the most promising congeners also show pronounced antiviral activity against the human coronaviruses HCoV-229E and HCoV-OC43, with EC50 values ranging from 0.2 to 9.4 mu M. The presence of a 6,7-dimethoxytetrahydroisoquinoline group at the C-4 position of the 2phenylquinoline core gave compound 6g that showed potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks.

Automated summary

In this study, a compound with potential antiviral activity was identified from a selection of compounds. This compound showed promising activity in the severe phenotypic-based screening assay. Further experiments demonstrated that this compound and its analogues had low toxicity and inhibited the replication of SARS-CoV-2. They also exhibited antiviral activity against other human coronaviruses. Additionally, the compound showed potent inhibition against the SARS-CoV-2 helicase, highlighting its potential against emerging coronavirus outbreaks.